Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Amgen Says Denosumab Similar to Zometa in Study

By Pharmaceutical Processing | August 4, 2009

THOUSAND OAKS, Calif. (AP) — Amgen Inc. said Monday its drug denosumab met the goals of a late-stage study in treating patients with cancer that has spread to their bones, as it performed similarly to Novartis AG’s drug Zometa. The trial compared denosumab and Zometa in the treatment of bone metastases in 1,776 advanced cancer patients. Amgen said the two drugs had similar effects in delaying the length of time until a patient’s first bone injury and subsequent bone injuries. The company said denosumab was superior in both measurements, but the difference was not statistically significant. The bone injuries included fracture, radiation or surgery to bone, or spinal cord compression. Patients in the study received either a 120 mg subcutaneous injection of denosumab once every four weeks, or a 4 mg, 15-minute infusion of Zometa every four weeks. Amgen is seeking marketing approval for denosumab as a treatment for osteoporosis, and for the prevention of bone loss in patients being treated for breast or prostate cancer. The most recent study excluded patients with breast and prostate cancer, however. Amgen reported results from another late-stage trial in July. In that study, which involved patients with breast cancer that had spread to the bone, Amgen said cancer patients who were treated with denosumab were free of skeletal injury for longer than those who took Zometa. Results from a third study have not yet been reported. A Food and Drug Administration is scheduled to review Amgen’s marketing application for denosumab on Aug. 13, and is expected to make a decision by October.

Related Articles Read More >

Doctor, woman patient and tablet for consulting with results, medical info and talk for healthcare with mockup space. Japanese medic, digital touchscreen or show video for surgery, wellness or advice.
Putting patients first in clinical trials
Confidently navigate the transition from bench to batch
Merck
FDA approves Merck’s Winrevair to treat pulmonary arterial hypertension
kobayashi pharmaceutical logo
Report: Japan health authorities investigate Kobayashi Pharmaceutical factory after five deaths
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE